Imricor Awarded NIH Contract

27 September 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided ablation products, is pleased to announce it was awarded a contract from the US National Insitutues of Health (NIH) to develop an MRI comptabile myocardial biopsy system. Under the agreement, Imricor will receive US$399,539 over the next 12 months to develop a prototype system of devices that biopsy the inner walls of the heart, while using MR imaging to guide the procedure.

Imricor’s Vice President of Research and Clinical, Tom Lloyd, is the Principal Investigator for the project. Mr Lloyd commented: “We hace revieced a significant intrest from the physicians for the development of an MR compatible biopsy system, a testament to the success of Imricor’s technology after bringing the world’s first MRI comptabile cardiac ablation catheter to the market. We are very excited to engage with the NIH to develop this prototype biopsy system which has the potential to mark our first product line expansion beyond cardiac ablation.”

~ ~ ~ ~ ~
About Imricor